Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 43.69 | 1.28 | 0.96 | 0.76 |
| FCF Yield | 5.46% | 3.70% | 3.33% | 3.78% |
| EV / EBITDA | 8.55 | 12.04 | 13.31 | 10.33 |
| Quality | ||||
| ROIC | 8.41% | 11.45% | 11.20% | 10.57% |
| Gross Margin | 54.88% | 58.07% | 57.58% | 58.35% |
| Cash Conversion Ratio | 1.19 | 1.11 | 0.90 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.95% | 10.70% | 9.65% | 1.96% |
| Free Cash Flow Growth | 9.88% | 20.54% | 31.99% | 64.08% |
| Safety | ||||
| Net Debt / EBITDA | -0.48 | -1.56 | -1.61 | -1.44 |
| Interest Coverage | 40.53 | 204.33 | 137.49 | 118.34 |
| Efficiency | ||||
| Inventory Turnover | 2.26 | 2.43 | 2.47 | 2.48 |
| Cash Conversion Cycle | 186.25 | 175.22 | 173.32 | 170.24 |